Please support MJHS Institute
Facebook Twitter YouTube LinkedIn

Interprofessional Webinar Series:
Update on Adjuvant Analgesics in Advanced Illness

This webinar is presented in collaboration with the
National Hospice and Palliative Care Organization.

Funding Disclosure: No commercial funding has been accepted for the activity.

Date and Time: October 6, 2016, 12:30 PM – 1:30 PM ET (Live)

Location: Online at

Speaker Name and Title:
Russell K. Portenoy, MD
Chief Medical Officer, MJHS Hospice and Palliative Care, New York, NY
Executive Director, MJHS Institute for Innovation in Palliative Care, New York, NY
Professor of Neurology and Family and Social Medicine,
Albert Einstein College of Medicine, Bronx, NY

Purpose: The effective use of adjuvant analgesics is considered a best practice in the management of specific types of chronic pain experienced by populations with advanced illness, particularly cancer populations. This webinar will present the evidence in support of the efficacy and safety of the various drug classes that comprise the adjuvant analgesics and offer practical guidelines for the use of these drugs.

Why Do I Need to Know This?
Although opioids are highly effective across populations with advanced illness, a substantial proportion of patients, as many as one-third, are unable to achieve a favorable balance between analgesia and side effects. Poor responsiveness to opioids is more likely when chronic pain is related to neuropathic mechanisms. Bone pain and pain related to bowel obstruction also present clinical challenges. The use of adjuvant analgesics for neuropathic pain, bone pain, and pain due to bowel obstruction is evidence-based and should be understood by all clinicians who manage pain in populations with advanced illness.


  1. Discuss the approach to opioid pharmacotherapy in patients with pain that may be treated with adjuvant analgesics.
  2. Describe the selection and dosing of first-line antidepressant and antiepileptic adjuvant analgesics.
  3. Identify best practices in the treatment of neuropathic pain and bone pain.

Target Audience: palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, pharmacists, allied health professionals, fellows, residents, and medical students.

Criteria for Successful Completion:

  1. Attendance at entire session (mandatory for nurses and pharmacists)
  2. Submission of completed evaluation form (mandatory to receive CE/CME credit for MDs, nurses)
  3. Submission of completed Verification of Continuing Education Participation Form, Program Evaluation Form, and CE Validation Form (mandatory for pharmacists). Pharmacists must email all three forms to Shelita Clark at or fax forms to 212-649-5544 within 45 days of webinar date.

Continuing Education Credits: 1.0

Continuing Education Accreditation:

Physicians:  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Hospice and Palliative Care Organization (NHPCO) and MJHS. NHPCO is accredited by the ACCME to provide continuing medical education for physicians.

NHPCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses:  NHPCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NHPCO designates this live activity for a maximum of 1.0 contact hour. Nurses should claim only the contact hours commensurate with the extent of their participation in the activity. Accredited status by ANCC refers only to continuing nursing education and does not imply endorsement of any commercial product discussed in conjunction with this activity.


Pharmacists:  St. John’s University College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this program provides a total of 1.0 hours of home-study continuing education credit. In order to obtain credit, participants must complete and submit required continuing education forms. The Universal Activity Number assigned to this program is: 0043-9999-16-077-H01-P . Credit will be posted to CPE Monitor within six weeks.

Individual:  $25 (includes CME/CE certificate)
Group:  $65 + $5 per CME/CE certificate

Registration fees for webinars are not refundable.

System Requirements for Computers and Mobile Devices:


Russell K. Portenoy, MD, Faculty and Planner, has indicated a relationship with Pfizer Inc. and with AstraZeneca Pharmaceuticals LP for research grant support. Any discussion of investigational or unlabeled uses of a product will be identified.

No other Planning Committee Member has any disclosures.

Planning Committee Members
Barbara Bouton, MA, FT
Colleen Fleming-Damon, PhDc, APRN-BC, ACHPN-BC, C.T.
Steven R. Gardner, MPA, PAHM
Myra Glajchen, DSW
Jennifer Kennedy, RN, MA, BSN, CHC
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Judith A. Skretny